Press release
Oxipit ChestEye secures medical device certification in Australia
"Australia presents a very advanced, well developed healthcare landscape. As in other advanced economies, there is a significant shortage of radiology specialists, inviting innovations to improve radiology workflow and reporting productivity. Building upon our experience in European markets, we are excited to introduce vanguard ChestEye capabilities for better patient care" - notes Oxipit CEO Gediminas Peksys.
In Australian market ChestEye will be used to produce preliminary reports for chest X-Rays featuring no abnormality. The platform will mark no-finding chest X-ray images in the radiologist workflow, including only the images that the software can deem healthy with high confidence. The platform will then present a preliminary report, which can be augmented or approved after an assessment by the radiologist.
"In a clinical setting, especially in primary care facilities, approximately half of the chest X-rays feature no abnormality. Yet they still require reporting by a medical specialist. By identifying healthy patient X-rays with high confidence, ChestEye minimizes required radiologist intervention for report approval featuring no abnormalities" - notes CEO of Oxipit Gediminas Peksys.
ChestEye imaging suite can identify 75 radiological findings covering over 90% of radiological cases presented to a radiologist on a daily basis.
Earlier this year Oxipit ChestEye was selected as the winner in the prestigious World Summit Awards in healthcare and well-being category.
Oxipit.ai
Sauletekio al. 15, LT-10224 Vilnius
Lithuania
www.oxipit.ai
Oxipit is a computer vision software startup specialized in medical imaging. With a team of award-winning data scientists and medical doctors, the company aims to introduce innovative Artificial Intelligence/Deep Learning breakthroughs to everyday clinical practice. Oxipit is the authors of CE certified multi-award winning ChestEye radiology imaging suite.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oxipit ChestEye secures medical device certification in Australia here
News-ID: 1955813 • Views: …
More Releases from Oxipit
Oxipit Partners With CARPL To Increase Global Reach Of AI Diagnostic Products
At the European Congress of Radiology in Vienna Oxipit announced that its diagnostic AI solutions will be available on the CARPL platform. CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality - for real-time quality assurance and ChestEye - for preliminary reports. The move further builds on Oxipit strategy to increase global reach of company's products.
"CARPL is our…
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency's approval is one of Oxipit steps to increase global reach for company products.
"With many future-focused healthcare organizations, LatAm market shows tremendous potential for healthcare AI applications. Oxipit products have already shown strong market traction in the region. The ANVISA certification…
Oxipit Closes $4.9M Funding Round To Advance AI Autonomy in Medical Imaging
AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital and Practica Capital. Angel investors also participated in this round. The funding will help Oxipit advance its development of autonomous AI medical imaging applications and support market expansion into new geographic regions, with particular focus on the United Kingdom.
"2022 was a breakthrough year for the Oxipit team. In spring we introduced ChestLink - the first fully…
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
AI medical imaging company Oxipit expanded its Quality product suite with quality assurance support for musculoskeletal X-rays, mammography images and lung CT scans. Previously supporting only chest X-rays, the upgraded Quality suite aims to answer all imaging department quality assurance needs with a single product. The updated Quality product will be showcased at RSNA 2022 annual meeting later this month.
Oxipit Quality employs AI as the second reader for quality assurance.…
More Releases for ChestEye
Chest experts Oxipit and contextflow team up for diagnostic quality assurance
The new partnership aims to mitigate the risk associated with missed findings in CT medical imaging studies. The collaboration will combine Oxipit's ChestEye Quality and contextflow's SEARCH Lung CT products to identify missed findings in CT scans in near-real time. ECR 2022 will offer the first preview of the combined solution, and the first installation will be deployed at Leiden University Medical Center.
ChestEye Quality analyzes medical images and corresponding…
Oxipit to offer free of charge retrospective CXR quality audit at RSNA
At the annual RSNA meeting, the AI medical imaging company will present the new ChestEye Quality AI double reading tool. To showcase vanguard ChestEye Quality capabilities, Oxipit will offer a free-of-charge quality audit for 6 months of retrospective CXR data. ChestEye Quality is already deployed in multiple medical institutions across Europe. With 229.617 images processed, the platform helped to identify 20% extra clinically relevant nodules, as well as numerous missed…
Oxipit Receives Patent for Improved AI Lung Cancer Diagnostics
Oxipit, creators of artificial intelligence based radiology imaging suite ChestEye, announces that the European Patent Office has approved their patent application. The innovation allows efficient use of high-resolution chest X-ray images for machine learning model training and is especially relevant for improving lung nodule detection.
Modern X-ray equipment produces large images with 16 Megapixel resolution being common. On the other hand, machine learning and artificial intelligence (AI) algorithms are typically optimized…
New Oxipit service to aid large scale chest X-ray screening projects
The AI medical imaging company will showcase ChestEye Negative service at Arab Health 2020 conference in Dubai. ChestEye Negative produces preliminary reports for chest X-rays with no abnormality. The service aims to reduce the workload of radiologists, especially in clinical environments, where only a fraction of all studies features an abnormality. It also significantly simplifies large-scale medical screening projects.
"Large scale medical surveys - such as tuberculosis screening in migrant populations…
AI vs Radiologists: can AI surpass doctors in reporting accuracy?
A study by the Centre for Advanced Research in Imaging, Neuroscience and Genomics (CARING) found that nearly 80% of AI generated chest X-ray case reports were as accurate as produced by a radiology specialist. Furthermore, AI reports were more accurate in 5% of analyzed patient cases. The study was undertaken using Oxipit ChestEye AI imaging suite. The full study titled The full study titled “Judging the Accuracy and Clinical Validity…
Medical Imaging Company Oxipit raises $1.7M Seed Round to bring AI into Clinical …
Oxipit are the authors of ChestEye AI-powered radiology software suite. Automated AI-based diagnosis and reporting by ChestEye enables radiologists to improve productivity, reduce error-rate, discover overlooked secondary findings and address the shortage and ever-increasing workload of radiology specialists.
The round marks the largest investment for medical AI solutions in the Baltic states. It is also one of the largest seed rounds among Baltic startups.
In February ChestEye software received CE…
